Serum Bactericidal Activity of Extended-Release Clarithromycin Against Macrolide-Resistant Strains of Streptococcus pneumoniae

Study Objective. To investigate the serum bactericidal activity (SBA) over time of extended‐release clarithromycin against moderately resistant strains of Streptococcus pneumoniae. Design. Prospective, single‐dose pharmacodynamic study. Setting. University‐affiliated research center. Subjects. Eleve...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2002-05, Vol.22 (5), p.593-596
Main Authors: Stein, Gary E., Schooley, Sharon
Format: Article
Language:English
Subjects:
Adult
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - blood
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Clarithromycin - administration & dosage
Clarithromycin - blood
Clarithromycin - pharmacology
Delayed-Action Preparations
Drug Resistance
Genes, Bacterial - genetics
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pneumococcal Infections - microbiology
Serum Bactericidal Test
Streptococcus pneumoniae - drug effects
Streptococcus pneumoniae - genetics
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Objective. To investigate the serum bactericidal activity (SBA) over time of extended‐release clarithromycin against moderately resistant strains of Streptococcus pneumoniae. Design. Prospective, single‐dose pharmacodynamic study. Setting. University‐affiliated research center. Subjects. Eleven healthy male volunteers. Intervention. All volunteers received a single dose of extended‐release clarithromycin as two 500‐mg tablets, and blood samples were obtained at 0, 2, 6, 12, and 24 hours after administration of the dose. Measurements and Main Results. For each blood sample, a serum bactericidal titer (SBT) was determined against S. pneumoniae strains with minimum inhibitory concentrations (MICs) of 0.5, 1.0, 2.0, 4.0, and 8.0 μg/ml to clarithromycin. The median SBT was determined for each time period. The extended‐release formulation of clarithromycin exhibited SBA for 24 hours against pneumococcal strains with MICs of 0.5, 1.0, and 2.0 μg/ml. No SBA was observed against isolates with MICs of 4.0 or 8.0 μg/ml. Conclusion. The extended‐release formulation of clarithromycin, taken once/day, will provide SBA for 24 hours against strains of S. pneumoniae with MICs of 2.0 μg/ml or less.
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.22.8.593.33214